QYUNS: Reached a global exclusive licensing agreement with Roche for QX031N, receiving a $75 million upfront payment

智通財經
2025.10.28 09:52
荃信生物公告，公司與羅氏達成全球獨家合作與許可協議，根據協議，公司授予羅氏開發、生產及商業化 QX031N 的全球獨家權益。公司預計將獲得一次性、不可退還且不可抵扣的首付款 7500 萬美元，並有資格獲得與產品開發、監管批准及商業化相關的至多 9.95 億美元里程碑付款，以及潛在未來產品銷售的梯度特許權使用費。
Source: 智通財經 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.